Illumina (NASDAQ: ILMN) appoints Eli Lilly R&D leader to its board
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
Illumina, Inc. increased its Board of Directors from nine to ten members and appointed Daniel M. Skovronsky, M.D., Ph.D. as a director, effective June 16, 2026. He will stand for election at the company’s 2027 annual meeting of stockholders for a one-year term.
Dr. Skovronsky is deemed an independent director under applicable Nasdaq and SEC rules and will participate in Illumina’s non-employee director compensation programs. He currently serves as Chief Scientific and Product Officer of Eli Lilly and Company and President of Lilly Research Laboratories, bringing deep experience in drug discovery, clinical development, and translational medicine relevant to Illumina’s genomics and multiomics platforms.
Positive
- None.
Negative
- None.
8-K Event Classification
2 items: 5.02, 9.01
2 items
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Board size after change: 10 directors
Effective appointment date: June 16, 2026
Election timing: 2027 annual meeting
+1 more
4 metrics
Board size after change
10 directors
Board increased from nine to ten members on June 16, 2026
Effective appointment date
June 16, 2026
Date Daniel M. Skovronsky joined Illumina’s Board
Election timing
2027 annual meeting
Skovronsky to stand for election to a one-year term
Press release exhibit date
June 23, 2026
Exhibit 99.1 Illumina press release announcing appointment
Key Terms
independent director, Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Regulation S-K, non-employee director compensation programs, +1 more
5 terms
independent director regulatory
"Dr. Skovronsky qualifies as an independent director under the applicable rules of The Nasdaq Stock Market and the Securities and Exchange Commission."
An independent director is a member of a company's board of directors who is not involved in the company's day-to-day operations and has no significant relationships with the company that could influence their judgment. Their role is to provide unbiased oversight and ensure the company is managed in the best interests of all shareholders. This helps build trust and confidence among investors by promoting transparency and accountability.
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers regulatory
"Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers."
Regulation S-K regulatory
"Dr. Skovronsky is not a party to any transaction with the Company reportable under Item 404(a) of Regulation S-K under the Securities Act of 1933."
A set of U.S. Securities and Exchange Commission rules that tell public companies which narrative and qualitative details must be disclosed in filings, such as risk factors, management discussion, executive pay, legal proceedings and business description. Think of it as a standardized checklist or blueprint that ensures investors get the same types of background information from every company so they can compare risks, management quality and strategy before making investment decisions.
non-employee director compensation programs financial
"Dr. Skovronsky will participate in the non-employee director compensation programs described under “Director Compensation” in the Company’s proxy statement filed on April 9, 2026."
Inline XBRL technical
"104 Cover Page Interactive Data File (embedded within the Inline XBRL document)"
Inline XBRL is a file format for financial filings that embeds machine-readable data tags directly inside the human-readable report, so the same document can be read by people and parsed by software. For investors it makes extracting, comparing and verifying financial numbers faster and more reliable—like a grocery list where each item also has a barcode—reducing manual errors and speeding up analysis.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 8-K
Current Report
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 16, 2026
(Exact name of registrant as specified in its charter)
(Commission File Number)
| (State or other jurisdiction of incorporation) | (I.R.S. Employer Identification No.) | |||||||
(Address of principal executive offices) (Zip code)
(858 ) 202-4500
(Registrant’s telephone number, including area code)
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13a of the Exchange Act. o
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On June 16, 2026, the Board of Directors (the “Board”) of Illumina, Inc. (the “Company”) increased the size of the Board from nine to ten members and appointed Daniel M. Skovronsky, M.D., Ph.D., to serve on the Board, effective immediately. Dr. Skovronsky will stand for election at the Company’s 2027 annual meeting of stockholders to serve for a one-year term commencing with such meeting. Dr. Skovronsky qualifies as an independent director under the applicable rules of The Nasdaq Stock Market and the Securities and Exchange Commission. There is no arrangement or understanding between Dr. Skovronsky and any other person pursuant to which he was selected as a director. In addition, Dr. Skovronsky is not a party to any transaction with the Company reportable under Item 404(a) of Regulation S-K under the Securities Act of 1933. Dr. Skovronsky will participate in the non-employee director compensation programs described under “Director Compensation” in the Company’s proxy statement filed on April 9, 2026.
A copy of the press release announcing the appointment of Dr. Skovronsky is attached as Exhibit 99.1 to this Current Report on Form 8-K.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
99.1 Illumina, Inc. Press Release, dated June 23, 2026
104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
ILLUMINA, INC. | ||||||||||||||
| Date: | June 23, 2026 | By: | /s/ SCOTT DAVIES | |||||||||||
| Name: | Scott Davies | |||||||||||||
| Title: | Chief Legal Officer | |||||||||||||
Exhibit Index
| Exhibit Number | Description | |||||||
99.1 | Illumina, Inc. Press Release, dated June 23, 2026 | |||||||
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) | |||||||
 | ||||||||||||||
Daniel M. Skovronsky, MD, PhD, appointed to Illumina's Board of Directors
Eli Lilly and Company’s Chief Scientific and Product Officer brings pharmaceutical R&D and scientific leadership perspective to Illumina's Board
SAN DIEGO, June 23, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced the appointment of Daniel M. Skovronsky, MD, PhD, to its Board of Directors, effective June 16, 2026. Dr. Skovronsky brings extensive experience in drug discovery, clinical development and translational medicine, which are areas directly relevant to Illumina’s work advancing genomics and multiomics platforms.
"Dan brings a rare combination of scientific expertise, innovation leadership, and healthcare impact," said Jacob Thaysen, chief executive officer of Illumina. "His experience building and advancing large research portfolios gives our Board a perspective that can help strengthen Illumina's ability to drive innovation across genomics, multiomics, and precision medicine."
Dr. Skovronsky currently serves as Chief Scientific and Product Officer of Eli Lilly and Company and President of Lilly Research Laboratories, where he leads Lilly's global research and development organization and oversees commercial products across Lilly Cardiometabolic Health, Lilly Immunology, and Lilly Neuroscience.
He joined Lilly in 2010, following the acquisition of Avid Radiopharmaceuticals, a company he founded in 2004 and led as Chief Executive Officer. Since joining Lilly, he has held roles of increasing responsibility across the organization.
He previously served on the Board of Directors of Myriad Genetics, Inc.
Dr. Skovronsky received a Bachelor of Science in molecular biophysics and biochemistry from Yale University and earned both his MD and PhD from the University of Pennsylvania. He completed residency training in pathology and fellowship training in neuropathology at the Hospital of the University of Pennsylvania.
About Illumina
Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit illumina.com and connect with us on X, Facebook, LinkedIn, Instagram, TikTok, and YouTube.
Investors:
Illumina Investor Relations
858.291.6421
IR@illumina.com
Media:
Christine Douglass
PR@illumina.com
FAQ
What board change did Illumina (ILMN) announce in this 8-K?
Illumina increased its Board of Directors from nine to ten members and appointed Daniel M. Skovronsky, M.D., Ph.D., as a new director effective June 16, 2026, expanding its leadership with additional scientific and pharmaceutical expertise.
Who is Daniel M. Skovronsky and what is his current role at Eli Lilly?
Daniel M. Skovronsky serves as Chief Scientific and Product Officer of Eli Lilly and Company and President of Lilly Research Laboratories, leading Lilly’s global research and development organization and overseeing commercial products across cardiometabolic health, immunology, and neuroscience franchises.
When will Daniel M. Skovronsky stand for election to Illumina’s board?
Daniel M. Skovronsky will stand for election at Illumina’s 2027 annual meeting of stockholders, seeking a one-year term commencing with that meeting. Until then, he serves as a board appointee effective June 16, 2026, under the board’s expansion decision.
Is Daniel M. Skovronsky considered an independent director at Illumina (ILMN)?
Yes, Illumina states that Daniel M. Skovronsky qualifies as an independent director under applicable rules of The Nasdaq Stock Market and the Securities and Exchange Commission, meaning he meets established standards for independence from the company’s management and related-party relationships.
How will Daniel M. Skovronsky be compensated as an Illumina director?
Illumina indicates that Daniel M. Skovronsky will participate in the company’s non-employee director compensation programs, as described under “Director Compensation” in its proxy statement filed on April 9, 2026, aligning his compensation structure with other non-employee board members.